Otsuka Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Company announced today that the US FDA approved the supplemental New Drug Application for ABILIFY for the acute treatment of manic and mixed ...

Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Control of ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...

The first step to managing bipolar 1 disorder is getting diagnosed — something that can be easier said than done. People who have bipolar 1 experience extreme mood episodes that swing between elation ...

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

Bipolar disorder causes extreme mood swings that range from manic highs to depressive lows, disrupting every aspect of life.

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...

NEW YORK, May 21 (Reuters) - Bristol-Myers Squibb Co.'s schizophrenia drug Abilify proved effective as an add-on therapy for patients suffering from major depression who were not getting satisfactory ...

Adding another antidepressant to the mix was more helpful than switching agents in older adults with treatment-resistant depression, a two-step, open-label trial suggested. In the first step of the ...